Chamber and committees

I refer the member to the answer to question S6W-03321 on
‎ 18 October 2021. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

I refer the member to the answer to question S6W-03321 on
‎ 18 October 2021. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

I refer the member to the answer to question S6W-02628 on 14 September 2021. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.

I refer the member to the answer to question S6W-02628 on14 September 2021. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.

We have confirmed with Public Health Scotland (PHS) that there is a sentinel surveillance scheme. The symptomatic dataset is a very small sample; consequently, any potential analysis would not be robust. However, we are assured that the ZOE app does include Scottish data; moreover, PHS does not believe that there is any reason to assume Scottish only data would be different.

I refer the member to the answer to question S6T-00019 on 26 May 2021. The answer is available on the Parliament's website at: Official Report - Parliamentary Business : Scottish Parliament

Detailed workforce planning, in partnership with NHS Scotland health boards is underway to enable delivery of the next stage of COVID-19 vaccinations, alongside the seasonal influenza vaccination programme. On 05 July 2021, we provided health boards with the latest available planning assumptions and advice from the Joint Committee on Vaccination and Immunisation. This included workforce deployment requirements, broken down by health board, alongside planning information to enable health boards to continue to work towards building a sustainable vaccinations workforce. We will share further workforce planning information with MSPs shortly on the plans for the delivery of Covid-19 and seasonal influenza vaccinations across NHS Scotland this coming autumn.

The option for all women aged 71 and over to self-refer for a breast screening appointment will resume once capacity in all screening centres returns to pre-Covid or close to pre-Covid levels. This is based on the recommendation of the Scottish Screening Committee, the National Screening Oversight and the Breast Screening Programme Board, all three of whom are keeping the situation under regular review. They are also working closely with Health Boards to increase appointments and meet this criteria as soon as possible.

As breast cancer is the most common cancer in women, it can occur in more than one family member by chance, and most cases of breast cancers are not hereditary. However, particular genes, known as BRCA1 and BRCA2, can increase the risk of developing breast cancer, and these can be passed on from parent to child. Arrangements have therefore been made to ensure that women aged 71 and over can continue to be screened for the duration of the self-referral pause if they have been identified as being at very high risk because they have BRCA1 or BRCA2 genes.

We also continue to emphasise that everyone should remain symptom aware and report any symptoms to their GP immediately for these to be investigated.

While the Scottish Government has access to management information (MI) on the number of independent contractors participating in the Covid-19 vaccination programme. This MI has not been subject to the same level of validation and checking as National Statistics or Official Statistics. Therefore, the data are not publicly available; however, as individual Health Boards have responsibility for local deployment decisions, they are best placed to advise on the composition of their respective workforces.

The Scottish Government’s office of the Chief Medical Officer is working closely with the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency (MHRA) to prioritise potential treatments for COVID-19. Further results of well-designed randomised controlled clinical trials exploring treatment efficacy of ivermectin to treat COVID-19 are awaited.

The MHRA, together with an independent advisory group, continues to review the emerging body of evidence regarding potential medicines for treatment or prevention of COVID-19, including Ivermectin.

The MHRA advises that, at this time, no application has been received for a licence for ivermectin in the treatment of COVID-19, in the UK. However, should an application for a licence be made, then the MHRA has processes in place to expedite such an application, as required.